Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Adalimumab

Nature Reviews Drug Discovery volume 2, pages 693–694 (2003)Cite this article

Abstract

Adalimumab (Humira; Abbott), an antibody that binds specifically to the inflammatory cytokine TNF-α, was approved by the US FDA for the treatment of moderate to severe rheumatoid arthritis in December 2002. Does the launch of adalimumab, which is the first fully human antibody to be approved as a therapeutic, sound the death knoll for chimeric and humanized antibodies?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Adalimumab (D2E7).
Figure 2: Market for drugs to treat rheumatoid arthritis in US $ million.

References

  1. Smolen, J. S. & Steiner, G. Therapeutic strategies for rheumatoid arthritis. Nature Rev. Drug Discov. 2, 473–488 (2003).

    Article  CAS  Google Scholar 

  2. Feldmann, M. Development of anti-TNF therapy for rheumatoid arthritis. Nature Rev. Immunol. 2 364–371 (2002).

    Article  CAS  Google Scholar 

  3. FDA Drug Approvals List [online] (cited 14 Jul 2003) <http://www.fda.gov.cber/label/adalabb123102LB.pdf> (2002).

  4. Weinblatt, M. E. et al. Adalimumab, α fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48 35–45 (2003).

    Article  CAS  Google Scholar 

  5. Palladino, M. A. et al. Anti-TNF-α therapies: the next generation. Nature Rev. Drug Discov. 2, 736–746 (2003).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Decision Resources Inc., 260 Charles Street, Waltham, 02453, Massachusetts, USA

    Bornadata Bain

  2. Nature Reviews Drug Discovery,

    Melanie Brazil

Authors
  1. Bornadata Bain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melanie Brazil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bornadata Bain.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bain, B., Brazil, M. Adalimumab. Nat Rev Drug Discov 2, 693–694 (2003). https://doi.org/10.1038/nrd1182

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1182

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing